TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Position Lowered by Alliancebernstein L.P.

Alliancebernstein L.P. reduced its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 10.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 174,020 shares of the biopharmaceutical company's stock after selling 19,550 shares during the quarter. Alliancebernstein L.P. owned approximately 0.11% of TG Therapeutics worth $5,238,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Arizona State Retirement System grew its holdings in shares of TG Therapeutics by 0.9% during the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock valued at $1,283,000 after purchasing an additional 364 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares during the period. Brookstone Capital Management lifted its position in TG Therapeutics by 3.7% in the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock valued at $527,000 after purchasing an additional 624 shares during the last quarter. Daymark Wealth Partners LLC grew its position in TG Therapeutics by 1.7% in the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock worth $1,249,000 after purchasing an additional 689 shares during the last quarter. Finally, New York State Teachers Retirement System raised its holdings in shares of TG Therapeutics by 1.9% during the fourth quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company's stock valued at $1,317,000 after buying an additional 837 shares during the last quarter. Institutional investors own 58.58% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Price Performance

NASDAQ:TGTX traded up $0.11 during trading hours on Friday, reaching $38.32. 1,074,546 shares of the company's stock were exchanged, compared to its average volume of 3,106,858. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company has a market capitalization of $6.02 billion, a P/E ratio of -383.16 and a beta of 2.14. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $43.32. The business's 50-day simple moving average is $36.34 and its two-hundred day simple moving average is $31.85.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. The business had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. Sell-side analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.